Your browser doesn't support javascript.
loading
Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy.
Mitani, Yuichi; Honda, Mamoru; Mizushima, Yoshitaka; Mori, Makiko; Fukuoka, Kohei; Oshima, Koichi; Arakawa, Yuki; Taira, Katsuaki; Tanami, Yutaka; Koh, Katsuyoshi.
Afiliação
  • Mitani Y; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
  • Honda M; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
  • Mizushima Y; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
  • Mori M; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
  • Fukuoka K; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
  • Oshima K; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
  • Arakawa Y; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
  • Taira K; Department of Orthopedic Surgery, Saitama Children's Medical Center, Saitama, Japan.
  • Tanami Y; Department of Radiology, Saitama Children's Medical Center, Saitama, Japan.
  • Koh K; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Haemophilia ; 29(6): 1653-1655, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37707369
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Hemofilia A Limite: Humans Idioma: En Revista: Haemophilia Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Hemofilia A Limite: Humans Idioma: En Revista: Haemophilia Ano de publicação: 2023 Tipo de documento: Article